Literature DB >> 17411371

Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy.

Deborah Persaud1, Stuart C Ray, Joleen Kajdas, Aima Ahonkhai, George K Siberry, Kimberly Ferguson, Carrie Ziemniak, Thomas C Quinn, Joseph P Casazza, Steven Zeichner, Stephen J Gange, Douglas C Watson.   

Abstract

A longitudinal study of viral reservoirs in children initiating highly active antiretroviral therapy (HAART) in early infancy was undertaken to test the hypothesis that early effective treatment affects the persistence of replication-competent viral latency and the evolution of HIV-1 in resting CD4(+) T cells. An end point dilution culture assay was used to measure the frequencies of latently-infected resting CD4(+) T cells harboring replication-competent virus in early and late treated children. Gag, pol, and env also were sequenced and compared to pretreatment sequences. HIV-1-specific humoral and cellular immune responses were also assessed. Blood samples were obtained from 12 HIV-1-infected children who started HAART at a median of 1.9 months of age and who maintained suppression of HIV-1 replication for up to 5.5 years. Replication-competent HIV-1 was recovered from 10/12 (84%) subjects. Evolution in gag, pol, and env was restricted for years in early-treated children. HAART initiated from early infancy does not prevent the establishment of a reservoir of latent provirus, but does significantly limit the evolution of HIV-1 in viral reservoirs. The effect of early therapy on HIV-1 evolution may have implications for long-term pharmacologic control of HIV-1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17411371     DOI: 10.1089/aid.2006.0175

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  33 in total

1.  HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment.

Authors:  Katherine Luzuriaga; Barbara Tabak; Manuel Garber; Ya Hui Chen; Carrie Ziemniak; Margaret M McManus; Danielle Murray; Matthew C Strain; Douglas D Richman; Tae-Wook Chun; Coleen K Cunningham; Deborah Persaud
Journal:  J Infect Dis       Date:  2014-05-21       Impact factor: 5.226

2.  Delayed HIV detection among infants exposed to postnatal antiretroviral prophylaxis during breastfeeding.

Authors:  Caroline C King; Athena P Kourtis; Deborah Persaud; Julie A E Nelson; Carrie Ziemniak; Michael G Hudgens; Gerald Tegha; Charles S Chasela; Denise J Jamieson; Charles M van der Horst
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

3.  Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA.

Authors:  Julio C C Lorenzi; Yehuda Z Cohen; Lillian B Cohn; Edward F Kreider; John P Barton; Gerald H Learn; Thiago Oliveira; Christy L Lavine; Joshua A Horwitz; Allison Settler; Mila Jankovic; Michael S Seaman; Arup K Chakraborty; Beatrice H Hahn; Marina Caskey; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-21       Impact factor: 11.205

4.  Combining Cell and Gene Therapy in an Effort to Eradicate HIV.

Authors:  Thor A Wagner
Journal:  AIDS Patient Care STDS       Date:  2016-12       Impact factor: 5.078

5.  Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth.

Authors:  Zabrina L Brumme; Hanwei Sudderuddin; Carrie Ziemniak; Katherine Luzuriaga; Bradley R Jones; Jeffrey B Joy; Coleen K Cunningham; Thomas Greenough; Deborah Persaud
Journal:  AIDS       Date:  2019-02-01       Impact factor: 4.177

6.  A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen.

Authors:  Scott M Hammer; Heather Ribaudo; Roland Bassett; John W Mellors; Lisa M Demeter; Robert W Coombs; Judith Currier; Gene D Morse; John G Gerber; Ana I Martinez; William Spreen; Margaret A Fischl; Kathleen E Squires
Journal:  HIV Clin Trials       Date:  2010 Nov-Dec

7.  Absence of detectable HIV-1 viremia after treatment cessation in an infant.

Authors:  Deborah Persaud; Hannah Gay; Carrie Ziemniak; Ya Hui Chen; Michael Piatak; Tae-Wook Chun; Matthew Strain; Douglas Richman; Katherine Luzuriaga
Journal:  N Engl J Med       Date:  2013-10-23       Impact factor: 91.245

8.  Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy.

Authors:  Carlum Shiu; Coleen K Cunningham; Thomas Greenough; Petronella Muresan; Victor Sanchez-Merino; Vincent Carey; J Brooks Jackson; Carrie Ziemniak; Lawrence Fox; Marvin Belzer; Stuart C Ray; Katherine Luzuriaga; Deborah Persaud
Journal:  J Virol       Date:  2009-07-15       Impact factor: 5.103

9.  Adherence and viral suppression among infants and young children initiating protease inhibitor-based antiretroviral therapy.

Authors:  Chloe A Teasdale; Elaine J Abrams; Ashraf Coovadia; Renate Strehlau; Leigh Martens; Louise Kuhn
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

Review 10.  Modeling HIV persistence, the latent reservoir, and viral blips.

Authors:  Libin Rong; Alan S Perelson
Journal:  J Theor Biol       Date:  2009-06-17       Impact factor: 2.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.